Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients

Chest

Volumn 125, Issue 4, 2004, Pages 1372-1377

  Lee, Daniel K C ^a   Jackson, Catherine M ^a   Haggart, Kay ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adenosine monophosphate; Antihistamine; Asthma; Fexofenadine; Inhaled corticosteroid; Leukotriene receptor antagonist; Mediator antagonist; Montelukast

Indexed keywords

ADENOSINE PHOSPHATE; BECLOMETASONE DIPROPIONATE; FEXOFENADINE; MONTELUKAST; NITRIC OXIDE; SALBUTAMOL;

ADD ON THERAPY; ADULT; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATOPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; EVALUATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTERMETHOD COMPARISON; LYMPHOCYTE COUNT; MALE; MEASUREMENT; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 2042462033     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.4.1372     Document Type: Article

References (15)

1. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(suppl):S147-S334
2. Van Ganse E, Kaufman L, Derde MP, et al. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J 1997; 10:2216-2224
3. 1-antihistamines on AMP challenge in atopic asthma. J Allergy Clin Immunol 2003; 111:337-341
4. 1. Am J Respir Crit Care Med 2002; 165:327-331
5. van den Berge M, Kerstjens HA, Meijer RJ, et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 2001; 164:1127-1132
6. van den Berge M, Meijer RJ, Kerstjens HA, et al. PC(20) adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med 2001; 163:1546-1550
7. Lee DK, Gray RD, Lipworth BJ. Adenosine monophosphate bronchial provocation and the actions of asthma therapy. Clin Exp Allergy 2003; 33:287-294
8. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152:1107-1136
9. Tan KS, McFarlane LC, Lipworth BJ. Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Thorax 1997; 52:608-611
10. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations: the European Respiratory Society Task Force. Eur Respir J 1997; 10:1683-1693
11. Dempsey OJ, Wilson AM, Sims EJ, et al. Additive broncho-protective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest 2000; 117:950-953
12. Wilson AM, Dempsey OJ, Sims EJ, et al. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001; 119:1021-1026
13. Currie GP, Lee DK, Haggart K, et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003; 167:1232-1238
14. Currie GP, Haggart K, Lee DK, et al. Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clin Exp Allergy 2003; 33:783-788
15. Rafferty P, Beasley R, Holgate ST. The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5′ monophosphate in atopic asthma. Am Rev Respir Dis 1987; 136:369-373